References
- Wiltgen D, Benedetto IG, Mastella LS, Spritzer PM. Lipid accumulation product index: a reliable marker of cardiovascular risk in polycystic ovary syndrome. Hum Reprod 2009;24:1726–31
- Baranowska B, Kozbicka G, Jeske W, Abel-Fattah H. The role of endogenous opiates in the mechanism of inhibited luteinizing hormone (LH) secretion in women with anorexia nervosa. The effect of naloxone on LH, FSH, prolactin and 0-endorphin secretion. J Clin Endocrinol Metab 1984;59:412–16
- Homburg R. Androgen circle of polycystic ovary syndrome. Hum Reprod 2009;24:1548–55
- Deshmukh S. Polycystic ovarian syndrome. In: Allahbadia GN, ed. Infertility management made easy. Tunbridge Wells, England: Anshan Ltd; 2007:172–97
- Gehlert DR. Role of hypothalamic neuropeptide Y in feeding, and obesity. Neuropeptides 1999;33:329–38
- Wurm S, Neumeier M, Weigert J, et al. Plasma levels of leptin, omentin, collagenous repeat-containing sequence of 26-kDa protein (CORS-26) and adiponectin before and after oral glucose uptake in slim adults. Cardiovasc Diabetol 2007;6:7. doi:10.1186/1475-2840-6-7
- Kim HK, Youn BS, Shin MS, et al. Hypothalamic Angptl4/Fiaf is a novel regulator of food intake and body weight. Diabetes 2010;59:2772–80
- Azziz R, Carmina E, Dewailly D, et al. Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome. An Androgen Excess Society Guideline 2006;91:4237
- WHO. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rp Ser 2000;894:1–253
- Beck B, Burlet A, Nicolas J-P, Burlet C. hypothalamic neuropeptide Y (NPY) in obese Zucker rats: implications in feeding and sexual behavior. Physiol Behav 1990;47:449–53
- Kalra SP, Dube MG, Sahu A, et al. Neuropeptide Y secretion increases in the paraventricular nucleus in association with increased appetite for food. Proc Natl Acad Sci USA 1991;88:10931–5
- Baranowska B, Radzikowska M, Wasilewska-Dziubihska E, et al. Neuropeptide Y, leptin, galanin and insulin in women with polycystic ovary syndrome. Gynecol Endocrinol 1999; 13:344–51
- Pan H-Y, Guo L, Li Q. Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res Clin Pract 2010;88:29–33
- Choi JH, Rhee EJ, Kim KH, et al. Plasma omentin-1 levels are reduced in non-obese women with normal glucose tolerance and polycystic ovary syndrome. Eur J Endocrinol 2011;165:789–96
- Tan BK, Adya R, Farhatullah S, et al. Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes [serial online] 2008;57:801–8
- Oike Y, Akao M, Kubota Y, et al. Angiopoietin-like proteins: potential new targets for metabolic syndrome therapy. Trends Mol Med 2005;11:473–9